ValiRx Share Price | |
---|---|
Price | 3.10 |
Bid | 3.00 |
Ask | 3.20 |
Change | -0.20 (-6.06%) |
Volume | 422,814 |
Open | 3.30 |
High | 3.30 |
Low | 3.10 |
Prev. Close | 3.30 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 132.35m |
Market Capitalisation | £4.10m |
Market Size | 30,000 |
52 Week High | 14.75 |
52 Week High Date | 03-Nov-2023 |
52 Week Low | 3.10 |
52 Week Low Date | 07-May-2024 |
# Trades | 5 |
---|---|
Vol. Sold | 92,500 |
Sold Value | £2.98k |
Vol. Bought | 330,314 |
Bought Value | £10.35k |
PE Ratio | -1.013072 |
Earnings | -3.06 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
08-May-24 | 11:34:43 | 3.104 | 70,314 | Buy* | 3.00 | 3.20 | 2,183 | O Ordinary |
08-May-24 | 11:17:00 | 3.104 | 150,000 | Buy* | 3.00 | 3.20 | 4,656 | O Ordinary |
08-May-24 | 09:57:13 | 3.19 | 20,000 | Buy* | 3.00 | 3.20 | 638.00 | O Ordinary |
08-May-24 | 09:34:48 | 3.196 | 90,000 | Buy* | 3.00 | 3.20 | 2,876 | O Ordinary |
08-May-24 | 09:01:10 | 3.22 | 92,500 | Sell* | 3.20 | 3.40 | 2,979 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
07-Jul-22 | 07-Jul-22 | Placing | Gerald Desler held the position of CFO at the time of this trade.Gerald Desler | 10.00 | GBX | 25,000 | 128,668 |
07-Jul-22 | 07-Jul-22 | Placing | Kevin Cox held the position of Non-Executive Chairman at the time of this trade.Kevin Cox | 10.00 | GBX | 100,000 | 372,333 |
07-Jul-22 | 07-Jul-22 | Placing | Martin Lampshire held the position of Non-Executive Director at the time of this trade.Martin Lampshire | 10.00 | GBX | 100,000 | 144,000 |
07-Jul-22 | 07-Jul-22 | Placing | Suzanne Dilly held the position of CEO at the time of this trade.Suzanne Dilly | 10.00 | GBX | 100,000 | 416,668 |
18-Feb-21 | 18-Feb-21 | Buy | Martin Lampshire held the position of Non-Executive Director at the time of this trade.Martin Lampshire | 22.70 | GBX | 44,000 | 44,000 |
Click here to read more about our shareholder information - providing intellectual, corporate and financial support in the early stages of drug development.